Semaglutide

A GLP-1 receptor agonist with 94% sequence homology to native GLP-1, modified with a C18 fatty diacid chain for albumin binding. Half-life of approximately 7 days enables once-weekly injection. FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy). Clinical trials show 12–15% average body weight reduction. First GLP-1 agonist available in oral form (Rybelsus).